VANCOUVER, Canada, June 17, 2026
LIR Life Sciences Corp. announced the successful completion of its comparative preclinical animal study evaluating its protamine-enhanced skin permeation technology for the delivery of semaglutide and tirzepatide, two leading GLP-1-based obesity therapies. The completed mouse study demonstrated closely aligned and reproducible glucose-lowering responses for both molecules when administered through the company’s investigational topical formulation. According to the company, the results support the potential of its needle-free transdermal delivery platform to transport structurally different incretin therapies through the skin while producing meaningful blood glucose control following an oral glucose challenge. The findings strengthen evidence that the delivery technology may function as a platform approach rather than being limited to a single therapeutic molecule, providing an important milestone in the development of alternative administration methods for obesity and metabolic disease treatments.
Topical Semaglutide and Tirzepatide Show Comparable Glucose Control
The completed study compared topical protamine-enabled formulations of semaglutide and tirzepatide with standard subcutaneous injections and untreated controls using a standardized glucose tolerance model. Researchers observed that both topical formulations produced similar glucose response profiles, including reduced post-challenge glucose excursions and sustained glucose stability throughout the observation period. The comparable performance between the two therapies suggests that the protamine-enhanced skin permeation technology can consistently deliver different GLP-1/GIP receptor agonists without compromising biological activity. Since tirzepatide possesses a dual GLP-1/GIP receptor agonist mechanism that differs structurally from semaglutide, the findings provide additional confidence that the delivery platform may be molecule-agnostic, expanding its future applicability across multiple incretin-based therapies. Such an approach could potentially improve patient adherence by eliminating the need for injectable administration while maintaining therapeutic effectiveness.
Platform Supports Future Formulation Optimization and Clinical Development
Following completion of the comparative study, LIR Life Sciences plans to utilize the comprehensive dataset to guide formulation optimization, dose refinement, lead candidate selection, and future regulatory-enabling preclinical studies. Company leadership noted that demonstrating reproducible performance across two of the most widely recognized obesity therapies provides a stronger scientific foundation for advancing the platform toward human development. Chief Executive Officer Edward Mills emphasized that consistent outcomes across semaglutide and tirzepatide indicate a platform-level technology effect rather than an isolated result linked to a single compound. These findings may help support future development strategies focused on creating needle-free obesity treatments capable of improving accessibility, convenience, and long-term patient adherence while potentially reducing barriers associated with injectable medications.
ENDO 2026 Presentation Highlights Expanding Potential of Needle-Free Therapy
Advertisement
The company also confirmed that the completed study findings were presented at ENDO 2026, the annual scientific meeting of the Endocrine Society, held in Chicago, Illinois, where global researchers and clinicians gathered to discuss advances in endocrinology and metabolic disease. Presentation of the data at a leading international scientific congress provides additional visibility for LIR’s investigational delivery platform as interest continues to grow in non-invasive GLP-1 therapies. Beyond the preclinical results, the company announced that its Board of Directors approved the grant of 2.26 million Restricted Share Units (RSUs) to selected directors, officers, and consultants under its equity incentive plan. While the equity announcement represents a corporate update, the primary significance remains the successful completion of a study demonstrating that protamine-enabled transdermal delivery may offer a promising needle-free alternative for future GLP-1 and GIP-based obesity therapies, supporting continued development toward larger preclinical and regulatory milestones.
Source: LIR Life Sciences press release
